The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer's disease: A preliminary investigation

Current Alzheimer Research

Volumn 10, Issue 3, 2013, Pages 240-251

  Nathan, Pradeep J ^a,b   Boardley, Rebecca ^a   Scott, Nicola ^a   Berges, Alienor ^a   Maruff, Paul ^c   Sivananthan, Tharani ^a   Upton, Neil ^a   Lowy, Martin T ^d   Nestor, Peter J ^b,e   Lai, Robert ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GlaxoSmithKline ^*  (Australia)

^d GLAXOSMITHKLINE   (United States)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; Antagonist; Attention; Cognition; H3 receptor; Histamine; Memory; Safety; Tolerability

Indexed keywords

GSK 239512; HISTAMINE H3 RECEPTOR ANTAGONIST; OXAZEPAM; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLURRED VISION; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL CHEMISTRY; COGNITION; COGNITIVE DEFECT; CONFUSION; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DEPRESSION; DISORIENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; DYSURIA; EFFECT SIZE; EMOTIONAL DISORDER; EYE PAIN; FATIGUE; FEELING ABNORMAL; FEMALE; HALLUCINATION; HEADACHE; HEMATOLOGY; HUMAN; HYPERHIDROSIS; LETHARGY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SOMNOLENCE; TASK PERFORMANCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VERTIGO; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATTENTION; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H3 ANTAGONISTS; HUMANS; MALE; MEMORY; SINGLE-BLIND METHOD;

EID: 84876857387     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310030003     Document Type: Article

References (44)

1. Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 32(4): 242-9 (2011).
2. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 63(6): 637-72 (2001).
3. Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 526(2): 322-7 (1990).
4. Pollard H, Moreau J, Arrang JM, Schwartz JC. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 52(1): 169-89 (1993).
5. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321(3): 1032-45 (2007).
6. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302(5911): 832-7 (1983).
7. Clapham J, Kilpatrick GJ. Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. Br J Pharmacol 107(4): 919-23 (1992).
8. Blandina P, Giorgetti M, Bartolini L, Cecchi M, Timmerman H, Leurs R, et al. Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 119(8): 1656-64 (1996).
9. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287(2): 658-66 (1998).
10. 3recetptor: A target for new drugs. Amsterdam: Elsevier pp13-26 (1998).
11. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313(1): 176-90 (2005).
12. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28(51): 13805-14 (2008).
13. Whitehousase PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215(4537): 1237-9 (1982).
14. Cacabelos R, Yamatodani A, Niigawa H, Hariguchi S, Tada K, Nishimura T, et al. Brain histamine in Alzheimer's disease. Methods Find Exp Clin Pharmacol 11(5): 353-60 (1989).
15. Mazurkiewicz-Kwilecki IM, Nsonwah S. Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can J Physiol Pharmacol 67(1): 75-8 (1989).
16. Panula P, Rinne J, Kuokkanen K, Eriksson KS, Sallmen T, Kalimo H, et al. Neuronal histamine deficit in Alzheimer's disease. Neuroscience 82(4): 993-7 (1998).
17. Airaksinen MS, Paetau A, Paljärvi L, Reinikainen K, Riekkinen P, Suomalainen R, et al. Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience 44(2): 465-81 (1991).
18. Nakamura S, Takemura M, Ohnishi K, Suenaga T, Nishimura M, Akiguchi I, et al. Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer's disease. Neurosci Lett 151(2): 196-9 (1993).
19. Medhurst AD, Roberts JC, Lee J, Chen CP, Brown SH, Roman S, et al. Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice. Br J Pharmacol 157(1):130-8 (2009).
20. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with druglike properties. J Pharmacol Exp Ther 313(1): 165-75 (2005).
21. Bonaventure P, Letavic M, Dugovic C, Wilson S, Aluisio L, Pudiak C, et al. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 73(8): 1084-96 (2007).
22. Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 36(1):52-73 (2011).
23. Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32: 267-87 (2009).
24. Robbins TW, Roberts AC. Differential regulation of frontoexecutive function by the monoamines and acetylcholine. Cereb Cortex Suppl 1: i151-60 (2007).
25. Hancock AA, Fox GB. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 13(10): 1237-48 (2004).
26. Witkin JM, Nelson DL. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 103(1): 1-20 (2004).
27. Day M, Pan JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, et al. Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem Pharmacol 73(8): 1123-34 (2007).
28. Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, Lord B, Lovenberg TW. JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 56(8): 1131-7 (2009).
29. Southam E, Cilia J, Gartlon JE, Woolley ML, Lacroix LP, Jennings CA, et al. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology 201(4): 483-94 (2009).
30. Bardgett ME, Davis NN, Schultheis PJ, Griffith MS. Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol Learn Mem 95(1): 64-72 (2011).
31. Wilson DM, Bamford MJ, Beresford IJ, Brackenborough K, Briggs MA, et al. Identification of Clinical Candidates From The Benzazepine Class of Histamine H3 Receptor Antagonists. Medicinal Chemistry Letters (In review).
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (7): 939-44 (1984).
33. Moroney, JT. Meta-analysis of the Hachinski Ischaemic Score in pathologically verified dementias. Neurology 49: 1096-1105 (1997).
34. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatry Research 12: 397-408 (1975).
35. American Psychiatric Association. Diagnostic and statistical manual of mental health disorders (4th ed). Washington DC (1994).
36. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48(5 Suppl 6): S10-6 (1997).
37. Parrott AC, Hindmarch I. Factor analysis of a sleep evaluation questionnaire. Psychol Med 8: 325-329 (1978).
38. Wahle M, Häller S, Spiegel R. Validation of the NOSGER (Nurses' Observation Scale for Geriatric Patients): reliability and validity of a caregiver rating instrument. Int Psychogeriatr 8(4): 525-47 (1996).
39. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: U.S. Dept. of Health, Education, and Welfare (1976).
40. Thompson TA, Wilson PH, Snyder PJ, Pietrzak RH, Darby D, et al. Sensitivity and test-retest reliability of the international shopping list test in assessing verbal learning and memory in mild Alzheimer's disease. Arch Clin Neuropsychol 26(5): 412-24 (2011).
41. Lim YY, Ellis KA, Harrington K, Ames D, Martins RN, et al. The Aibl Research Group. Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol 34(4): 345-58 (2012).
42. Cho W, Maruff P, Connell J, Gargano C, Calder N, Doran S, et al. Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology 218(3): 513-24 (2011).
43. Ashworth S, Rabiner EA, Gunn RN, Plisson C, Wilson AA, Comley RA, et al. Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med 51(7): 1021-9 (2010).
44. Grove RA, Harrington C, Mahler A, Beresford I, Maruff P, Lowy M, et al. A randomised, double-blind, placebo-controlled 16 week study of the H3 receptor antagonist, GSK239512 as a monotherapy, in patients subjects with mild-to-moderate Alzheimer's disease. Curr Alz Res (2013) (submitted).